Novel system to investigate the effects of inhaled volume and rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler
- PMID: 12102616
- PMCID: PMC2751293
- DOI: 10.1208/ps040206
Novel system to investigate the effects of inhaled volume and rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler
Abstract
This study evaluated the effect of inhaled volume and simulated inspiratory flow rate ramps on fine particle output from dry powder inhalers (DPIs). A simple, robust system was developed to account for "rate of rise" (ramp) effects while maintaining a constant air flow through a multi-stage liquid impinger (MSLI), used for sizing the emitted particles. Ramps were programmed to reach 30 and 60 L/min over 100 milliseconds; 500 milliseconds; and 1, 2, and 3 seconds. Rotahaler was chosen as the test DPI. Testing was done with simulated inhalation volumes of 2 L and 4 L. Testing was also carried out using the USP apparatus 4. At 30 L/min, for a 2 L volume, the amount of drug exiting the device in fine particle fraction (FPF) increased from 2.33 microg to 6.04 microg from the 3-second ramp to the 100-millisecond ramp, with 11.64 microg in FPF for the USP (no ramp) method. At the same flow rate, for a 4 L volume, FPF increased from 2.23 microg to 8.45 microg, with 10.25 microg for the USP method. At 60 L/min, similar trends were observed. In general, at both flow rates, an increase in FPF was noted going from the shallowest to the steepest ramp. However, there were no significant differences in FPF when a 2 L inhaled volume was compared with a 4 L volume at each flow rate. Overall, these data suggest that the existing USP apparatus may overestimate FPF at flow rates lower than those recommended by the USP.
Similar articles
-
Effect of rise in simulated inspiratory flow rate and carrier particle size on powder emptying from dry powder inhalers.AAPS PharmSci. 2000;2(2):E10. doi: 10.1208/ps020210. AAPS PharmSci. 2000. PMID: 11741226 Free PMC article.
-
Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.Int J Pharm. 2006 Mar 9;310(1-2):81-9. doi: 10.1016/j.ijpharm.2005.11.029. Epub 2006 Jan 25. Int J Pharm. 2006. PMID: 16442246
-
Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size.J Pharm Sci. 2006 Jun;95(6):1382-92. doi: 10.1002/jps.20603. J Pharm Sci. 2006. PMID: 16625656
-
Do all dry powder inhalers show the same pharmaceutical performance?Int J Clin Pract Suppl. 2005 Dec;(149):7-12. doi: 10.1111/j.1368-504X.2005.00721.x. Int J Clin Pract Suppl. 2005. PMID: 16279997 Review.
-
Novolizer: the new technology for the management of asthma therapy.Curr Opin Pulm Med. 2003 Apr;9 Suppl 1:S11-6. Curr Opin Pulm Med. 2003. PMID: 12974537 Review.
Cited by
-
The abbreviated impactor measurement (AIM) concept: part II--Influence of evaporation of a volatile component-evaluation with a "droplet-producing" pressurized metered dose inhaler (pMDI)-based formulation containing ethanol as cosolvent.AAPS PharmSciTech. 2009;10(1):252-7. doi: 10.1208/s12249-009-9201-x. Epub 2009 Mar 17. AAPS PharmSciTech. 2009. PMID: 19291411 Free PMC article.
-
Developing ways to evaluate in the laboratory how inhalation devices will be used by patients and care-givers: the need for clinically appropriate testing.AAPS PharmSciTech. 2014 Oct;15(5):1275-91. doi: 10.1208/s12249-014-0145-4. Epub 2014 Jun 4. AAPS PharmSciTech. 2014. PMID: 24889732 Free PMC article.
-
Inhalation performance of physically mixed dry powders evaluated with a simple simulator for human inspiratory flow patterns.Pharm Res. 2010 Oct;27(10):2131-40. doi: 10.1007/s11095-010-0215-6. Epub 2010 Jul 14. Pharm Res. 2010. PMID: 20628789
-
Determination of the relative bioavailability of salbutamol to the lungs following inhalation from dry powder inhaler formulations containing drug substance manufactured by supercritical fluids and micronization.Pharm Res. 2007 Nov;24(11):2008-17. doi: 10.1007/s11095-007-9328-y. Epub 2007 May 18. Pharm Res. 2007. PMID: 17510755 Clinical Trial.
-
Influence of realistic inspiratory flow profiles on fine particle fractions of dry powder aerosol formulations.Pharm Res. 2007 Feb;24(2):361-9. doi: 10.1007/s11095-006-9156-5. Epub 2006 Dec 20. Pharm Res. 2007. PMID: 17177114 Clinical Trial.
References
-
- Ruben SM, Jimenez P, Duan DR, et al. Keratinocyte growth factor-2. US patent 6 077 692. June 20, 2000.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources